We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Über die Hälfte der neu zugelassenen Medikamente sind Biopharmazeutika.
- Abstract
According to a report by the Boston Consulting Group for the Association of Research-Based Pharmaceutical Companies (VFA), in 2022, more original biopharmaceuticals were approved in Germany than ever before. The sales of biopharmaceuticals increased by 10.5% compared to 2021, reaching 17.8 billion euros, while the sales of the entire pharmaceutical market only grew by 5.4% to 54.2 billion euros. The areas of oncology, immunology, and metabolic diseases are the highest-grossing sectors. Out of a total of 63 approved drugs with a new active ingredient, 37 were biopharmaceuticals. Medical biotechnology also experienced growth, with 135 companies in 2022 developing and marketing their own medications. The biopharmaceutical pipeline has more than doubled since 2005, from 256 clinical development candidates to 672 by the end of 2022. Despite these successes, VFA President Han Steutel emphasizes that the laws regarding health insurance financing are increasingly making Germany a less attractive location and that the achievements of biotechnology should not be jeopardized.
- Subjects
GERMANY; HEALTH insurance finance; HEALTH insurance laws; PHARMACEUTICAL industry; BIOPHARMACEUTICS; BOSTON Consulting Group Inc.; METABOLIC disorders
- Publication
Pharma + Food, 2023, Vol 26, Issue 4, p17
- ISSN
1434-8942
- Publication type
Article